Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01480349
Other study ID # 46249
Secondary ID 1RC1NS068943-01H
Status Completed
Phase N/A
First received November 23, 2011
Last updated December 21, 2017
Start date January 10, 2011
Est. completion date May 10, 2016

Study information

Verified date December 2017
Source University of Utah
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This multicenter, prospective pilot study will compare the effectiveness of two established procedures used in the treatment of post-hemorrhagic hydrocephalus in very low birth weight infants, specifically ventricular reservoirs and subgaleal shunts. The study is being conducted by the Hydrocephalus Clinical Research Network (HCRN), a network established to conduct multi-institutional clinical trials on pediatric hydrocephalus.


Description:

Intraventricular hemorrhage and post-hemorrhagic hydrocephalus remain a leading cause of mortality and long-term morbidity in premature infants. The two most common temporary cerebrospinal fluid (CSF) diversion procedures are the ventriculosubgaleal shunt (SGS) and an implanted ventricular reservoir (RES) for intermittent CSF removal. These methods are physiologically very different and their comparative effectiveness in treating hydrocephalus and possibly reducing the need for an eventual permanent CSF shunt is currently not known. The goal of this pilot study is to obtain information critical for planning and executing a future randomized trial comparing SGS and RES. Specifically, this pilot study will establish inclusion criteria, define the primary outcome, and standardize the interventions in preparation for initiating a comparative trial between the SGS and RES procedures. In addition, the importance of examining the neurodevelopmental outcomes for these patients has been recognized within the neurosurgical and neuropsychological settings. Therefore, the scope of this study has been extended to include an examination of the neurodevelopmental outcomes at 18 to 22 months and at 36 to 42 months in patients who undergo BSID-III testing at their clinical centers.


Recruitment information / eligibility

Status Completed
Enrollment 146
Est. completion date May 10, 2016
Est. primary completion date May 10, 2016
Accepts healthy volunteers No
Gender All
Age group N/A to 180 Days
Eligibility Inclusion Criteria:

- premature neonates with birth weights less than 1500 grams

- Grade III or IV intraventricular hemorrhage

- Fronto-occipital horn ratio greater than or equal to 0.50

Exclusion Criteria:

- Less than 72 hour life expectancy from other medical problems

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada Sick Children's Hospital Toronto Ontario
United States Children's Hospital of Alabama Birmingham Alabama
United States Texas Children's Hospital Houston Texas
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States St. Louis Children's Hospital Saint Louis Missouri
United States Primary Children's Hospital Salt Lake City Utah
United States Seattle Children's Hospital Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Utah National Institute of Neurological Disorders and Stroke (NINDS)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Specific Aim I: Proportion of temporization The proportion of all infants entering the study who meet the criteria for surgical temporization. 5 years
Primary Specific Aim 2: Conversion proportion The proportion of all infants with SGS or RES who met criteria for conversion to permanent shunt. 5 years
Primary Specific Aim 3: Surgery Checklist Scores Surgery checklist scores of individual surgeon performance in standardized procedures. 5 years
Secondary Protocol adherence Protocol adherence by network, center, surgeon, decision rubric, and individual decision data points. 5 years
Secondary CSF Infection Incidence of CSF infection while on the protocol. 5 years
Secondary Neurodevelopmental Outcomes Subscores from the Bayley Scales of Infant Development, version III (BSID-III) to include cognitive, language and motor subtests will be obtained for patients undergoing BSID-III testing at 18-22 and 36-42 months of age. 7 years
See also
  Status Clinical Trial Phase
Completed NCT00747682 - Cerebral Perfusion, Oxygenation, Electrical Activity N/A